Abstract:B-precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related death in young people and commonly has poor outcomes in adults. Dysregulation of cytokine signaling frequently occur in high-risk ALL and correlates with poor prognosis. Molecular insight into activation of oncogenic cytokine signaling comes from the recent discovery of loss-of-function mutations in the adaptor protein LNK (or SH2B3) and constitutive active JAK2 mutations in Ph-like pediatric B-ALL, the subtype that lacks Philadelphia (Ph) chromosome translocation, yet displays a similar activated kinase signature to Ph+ ALL. While clearly established at the genetic level, mechanisms by which LNK mutation impacts ALL initiation or progression have not been established. Here we show that LNK synergizes with TP53 in suppressing B-ALL development in mice. Lnk-/-Tp53-/- B-ALLs are highly aggressive with 100% penetrance. More importantly, Lnk-/-Tp53-/- B blasts specifically exhibit gene signatures of human Ph-like ALL. Mechanistically, we demonstrate that B progenitors from preleukemic Lnk-/-Tp53-/- mice are hypersensitive to IL-7 and display marked self-renewal ability in vitro and in vivo. Using a novel phosphoflow strategy that enables interrogation of early transformative signaling events in B progenitors at different stages, we find that Lnk deficiency confers a heightened sensitivity to IL-7 in activating pStat5 in pro B progenitors. Furthermore, Lnk-/-Tp53-/- B blasts show constitutive activation of pAkt and pS6, but still depend on IL-7 for activation of Stat5. Moreover, Lnk-/-Tp53-/- B blasts are less sensitive to JAK inhibitors than normal B progenitors, consistent with the inability of JAK inhibition to eradicate B-ALL in humans. High-risk B-ALLs that show genetic mutations in cytokine dependent pathways and elevated cytokine signaling have poor survival rates. Our research focuses on a novel B-ALL mouse model to decipher mechanisms underlying high-risk ALL, and will enhance our understanding of this incurable disease and provide novel insights into therapeutic strategies. B-precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related death in young people and commonly has poor outcomes in adults. Dysregulation of cytokine signaling frequently occur in high-risk ALL and correlates with poor prognosis. Molecular insight into activation of oncogenic cytokine signaling comes from the recent discovery of loss-of-function mutations in the adaptor protein LNK (or SH2B3) and constitutive active JAK2 mutations in Ph-like pediatric B-ALL, the subtype that lacks Philadelphia (Ph) chromosome translocation, yet displays a similar activated kinase signature to Ph+ ALL. While clearly established at the genetic level, mechanisms by which LNK mutation impacts ALL initiation or progression have not been established. Here we show that LNK synergizes with TP53 in suppressing B-ALL development in mice. Lnk-/-Tp53-/- B-ALLs are highly aggressive with 100% penetrance. More importantly, Lnk-/-Tp53-/- B blasts specifically exhibit gene signatures of human Ph-like ALL. Mechanistically, we demonstrate that B progenitors from preleukemic Lnk-/-Tp53-/- mice are hypersensitive to IL-7 and display marked self-renewal ability in vitro and in vivo. Using a novel phosphoflow strategy that enables interrogation of early transformative signaling events in B progenitors at different stages, we find that Lnk deficiency confers a heightened sensitivity to IL-7 in activating pStat5 in pro B progenitors. Furthermore, Lnk-/-Tp53-/- B blasts show constitutive activation of pAkt and pS6, but still depend on IL-7 for activation of Stat5. Moreover, Lnk-/-Tp53-/- B blasts are less sensitive to JAK inhibitors than normal B progenitors, consistent with the inability of JAK inhibition to eradicate B-ALL in humans. High-risk B-ALLs that show genetic mutations in cytokine dependent pathways and elevated cytokine signaling have poor survival rates. Our research focuses on a novel B-ALL mouse model to decipher mechanisms underlying high-risk ALL, and will enhance our understanding of this incurable disease and provide novel insights into therapeutic strategies.

Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice

An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?

Abstract B57: A Combination of IL7Rα and NRAS Mutations Sheds Light on the Oncogenesis of T-cell Acute Lymphoblastic Leukemia in a Murine Model

A combination of IL7R alpha and NRAS mutations sheds light on the oncogenesis of T-cell acute lymphoblastic leukemia in a murine model

Identification of Genetic Alterations Associated with Mutant Il7ralpha in T-All

Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

Mutations that collaborate with IL-7Ra signaling pathways to drive ALL

Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.

Abstract 2462: A Combination of IL7Rα and NRAS Mutations Up-Regulates Bcl-2 and Cmyc Levels Leading to Formation of T-cell Acute Lymphoblastic Leukemia

ID: 64: Targeting the IL-7R pathway in leukemia

LNK/SH2B3 Regulates IL-7 Receptor Signaling in Normal and Malignant B-progenitors.

Oncogenic IL7R Gain-of-function Mutations in Childhood T-cell Acute Lymphoblastic Leukemia.

A novel tumor suppressor sh2b3 in acute lymphoblastic leukemia

O023 Oncogenic IL-7R Gain-of-function Mutations in Childhood T-ALL

Lnk (Sh2b3) Synergizes With Tp53 In Suppressing B-Precursor Acute Lymphoblastic Leukemia Through Il-7 Receptor Signaling

New Anti-Il-7rα Monoclonal Antibodies Show Efficacy Against T Cell Acute Lymphoblastic Leukemia in Pre-Clinical Models

Constitutive Ras Signaling and Ink4a/Arf Inactivation Cooperate During the Development of B-ALL in Mice.

SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia

ID: 64